Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127738 | 0.90 | UPP1 (0.43) | UPP1ALDH1A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL130534 | 0.78 | ALDH1A1 (0.39) | UPP1MKNK1MKNK2PDE3BPDE3A | |
| SCHEMBL127842 | 0.75 | ALDH1A1 (0.40) | UPP1PDE3BPDE3AALDH1A1CYP2C9 | |
| SCHEMBL132426 | 0.74 | ALDH1A1 (0.39) | UPP1PDE3BPDE3AALDH1A1CYP2C9 | |
| SCHEMBL128833 | 0.74 | ALDH1A1 (0.39) | UPP1ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL128976 | 0.69 | HSD17B10 (0.42) | PDE3BPDE3AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL127801 | 0.68 | UPP1 (0.45) | UPP1ALDH1A1 | |
| SCHEMBL6719842 | 0.65 | ALDH1A1 (0.52) | UPP1ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL126126 | 0.65 | ALDH1A1 (0.47) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL128689 | 0.64 | UPP1 (0.41) | UPP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | UPP1 4479/4885MKNK1 4026/4885MKNK2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.